In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA unveils a new Plausible Mechanism Pathway to accelerate drug reviews, and Ovid Therapeutics and Metagenomi share key third-quarter results and leadership changes.
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences industry.
In today’s Pharmaceutical Executive Daily, WeightWatchers plans to offer Novo Nordisk’s oral Wegovy pending FDA approval, FDA unveils a new Plausible Mechanism Pathway to accelerate drug reviews, and Ovid Therapeutics and Metagenomi share key third-quarter results and leadership changes.
WeightWatchers announced plans to offer Novo Nordisk’s oral version of Wegovy through its platform if the treatment receives FDA approval next year. The partnership would expand access to the GLP-1 therapy via direct consumer channels and continue WeightWatchers’ shift toward clinically integrated weight-management offerings.
The FDA has introduced a new Plausible Mechanism Pathway, designed to streamline reviews for therapies with strong mechanistic rationales and early evidence of benefit. The pathway aims to shorten development timelines and expand regulatory flexibility for innovative products addressing unmet medical needs.
Meanwhile, Ovid Therapeutics and Metagenomi released their third-quarter 2025 results, highlighting progress across genetic medicine and neurology programs. Both companies announced leadership updates as they advance key development milestones into the next fiscal year.
Thanks for listening to Pharmaceutical Executive Daily. For more updates and in-depth analysis, visit PharmExec.com.
